Beam Therapeutics (BEAM) Stock News
$BEAM · NASDAQ · HEALTHCARE · 2 stories in 30 daysBORSA has published 2 stories on Beam Therapeutics (BEAM) in the past 30 days. BORSA’s news read on BEAM is bullish at 68/100, based on 2 company events over the past 7 days. Beam Therapeutics’ next earnings report is scheduled for Tuesday, Nov 3.
The wire on $BEAM
newest first · updated · direct subject stories onlyBeam Therapeutics expects its cash runway to support operating plans into mid-2029. That extends the company's funding horizon and reduces the near-term need for new capital if spending stays on plan. The update did not include the cash balance, burn rate or assumptions behind the runway estimate.
bullish 70 · impact 40Beam Therapeutics reported $1B in cash, cash equivalents, and marketable securities at the end of the third quarter of 2026. The cash position is a key metric for a clinical-stage biotech, indicating runway for operations and R&D without near-term dilution. Investors will watch for upcoming earnings details on cash burn and pipeline progress.
· impact 40